(SNY) Community Analysis from
Bulls REASONS TO BUY
|
90%
agree
20 votes
|
Robust pipeline with over 125 drugs in development |
|
100%
agree
2 votes
|
Strong global franchise |
|
100%
agree
1 votes
|
First in class drugs |
Bears REASONS TO SELL
|
40%
agree
10 votes
|
Highly concentrated in a few blockbuster drugs like Lovenex and Plavix |
|
20%
agree
5 votes
|
FDA refused to approve obesity drug Accomplia |
May 23, 2013
(Stock Blog Hub,
5/16/13)
Sanofi (SNY) reported first quarter 2013 business earnings of 81 cents per American Depository Share (ADS), below the Zacks Consensus Estimate of 89 cents. Earnings were down...(read more)
(Stock Blog Hub,
4/11/13)
Sanofi (SNY) recently entered into a collaboration Transgene for the production of immunotherapy products and creating of an industrial platform for the same. The platform will...(read more)
(Wealth Daily,
2/13/13)
As part of the companies' ten-year partnership, Sanofi SA (EPA: SAN) will increase its stake in Regeneron Pharmaceuticals (NASDAQ: REGN) to 30%, possibly going beyond that in the years to come...
Sanofi-Aventis SA (SNY) Company Overview
There is no analysis for SNY yet. But you can go to Wikinvest to help create one!
What's in this SNY analysis on Wikinvest...
- Corporate Overview
- History
- Recent Acquisitions
- Business Segments
- Pharmaceuticals (€26.6 billion)[6]
- Thrombosis: Plavix & Lovenex (€4.89B in FY 2010)
- Cardiovascular Disease: Aprovel (€1.33B in FY 2010)
- Metabolic Disorder (Diabetes): Lantus (€3.5B in FY 2010
- Oncology (Cancer Treatment): Taxotere & Eloxatine (€2.5B in FY 2010)
- Vaccines (€3.8B in FY 2010)[7]
- Other Business Segments (€3.7B in FY 2010)[10]
- Research & Development (€4.4B in FY 2010)
- Trends & Forces
- Patent Expirations
- Aging Populations
- Emerging Markets
- The Weakening Dollar
- Major Acquisitions
- Unfavorable Legislative Environments
- Tightening FDA Regulations
- Vaccine Demand
- Competition
- References
